Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endothelial Dysfunction Protocol in COVID-19
NCT04631536Phase 3Unknown
- Sponsor
- LAU Medical Center-Rizk Hospital
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin, nicorandil, nebivolol, folic acid, arginine in coronavirus disease 2019 (COVID-19), sponsored by LAU Medical Center-Rizk Hospital. Status: unknown.
02
Drugs
atorvastatinnicorandilnebivololfolic acidarginine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04631536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631536.